Dianthus Therapeutics, Inc. (DNTH)
Automate Your Wheel Strategy on DNTH
With Tiblio's Option Bot, you can configure your own wheel strategy including DNTH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Published: March 09, 2026 by: Zacks Investment Research
Sentiment: Negative
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $1.43 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $0.81 per share a year ago.
Read More
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Published: March 09, 2026 by: Zacks Investment Research
Sentiment: Negative
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $1.43 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $0.81 per share a year ago.
Read More
Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism
Published: March 09, 2026 by: Benzinga
Sentiment: Positive
CIDP is a rare, acquired autoimmune disorder where the immune system damages the myelin sheath of peripheral nerves, causing progressive or relapsing muscle weakness, numbness, and sensory loss lasting over 8 weeks.
Read More
Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism
Published: March 09, 2026 by: Benzinga
Sentiment: Positive
CIDP is a rare, acquired autoimmune disorder where the immune system damages the myelin sheath of peripheral nerves, causing progressive or relapsing muscle weakness, numbness, and sensory loss lasting over 8 weeks.
Read More
Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar?
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Dianthus Therapeutics, Inc. (DNTH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Dianthus Therapeutics, Inc. (DNTH) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Published: February 16, 2026 by: Seeking Alpha
Sentiment: Neutral
Dianthus Therapeutics, Inc. (DNTH) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Read More
Dianthus Therapeutics, Inc. (DNTH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 15, 2026 by: Seeking Alpha
Sentiment: Neutral
Dianthus Therapeutics, Inc. (DNTH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy?
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Dianthus Therapeutics, Inc. (DNTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
Published: October 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing
Read More
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Dianthus Therapeutics, Inc. (DNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the following investor conferences:
Read More
About Dianthus Therapeutics, Inc. (DNTH)
- IPO Date 2018-06-21
- Website https://dianthustx.com
- Industry Biotechnology
- CEO Marino Garcia
- Employees 78